Prescriber, operator, purchaser, payer and patient — separate incentives — neonatal hyperbilirubinemia home phototherapy

1. Summary

The domain dossier's user-groups section had flagged the purchaser role as entirely unestablished for US home phototherapy, and named the prescriber and payer rows as resting mostly on reasoning or on non-US material. This pass finds that two independent, non-affiliated US payers — a North Carolina Medicaid/commercial managed-care plan (Elevance Health-affiliated) and a Louisiana Medicaid managed-care plan (a Centene subsidiary) — each publish an active clinical coverage policy specifically for home phototherapy, and both name the same two HCPCS codes for it and both require the equipment to come from a durable medical equipment (DME) provider rather than the birth hospital or the family directly [1][2]. Two independent DME/home-health companies' own patient- and insurer-facing documents show what that channel looks like in practice: a Rhode Island home-health company under contract to the regional Blue Cross plan bills the insurer directly and only charges the family's card on file if coverage is denied, while a separate, multi-state rental company instead has the family front payment at rental time and file an insurer claim itself using a company-supplied billing sheet [4][5]. The prescriber role is named in payer criteria as "a primary provider willing to manage home care" against a defined follow-up window, and separately, in one US trial's own enrollment criterion, as "the attending neonatologist" [2][7]. No US patient-preference survey for home phototherapy was located this pass; the closest US-specific patient-facing statement is a single DME company's FAQ stating the family retains the right to choose hospital readmission over home treatment instead [4].

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Prescriber / decider — named in payer criteria and in one trial's enrollment language, not in a US survey

Two independent, non-affiliated US payer coverage policies condition reimbursement on documented criteria rather than clinician judgment alone, and one of the two names the ordering clinician's own commitment as a coverage requirement: Louisiana Healthcare Connections' policy requires "A primary provider willing to manage home care with established follow-up within the next 24-48 hours" [2] [single-source]. Healthy Blue North Carolina's Clinical UM Guideline CG-DME-12 instead ties the decision to a numeric bilirubin margin, requiring that "Total serum bilirubin concentration is no more than 1 mg/dL above the phototherapy treatment threshold as defined by the American Academy of Pediatrics Clinical Practice Guideline" [1] [single-source]. Separately, the American Academy of Family Physicians' own summary of the 2022 AAP guideline states that at discharge, "the last bilirubin measurement and the age at which it was measured, treatments provided, and important laboratory results should be given to the primary care physician or families to facilitate the transition of care" [3] — naming a handoff from the birth-hospital team to a primary care physician without stating which of the two makes the ongoing treatment decision. In one US interventional trial, the enrollment criterion for phototherapy itself was hyperbilirubinemia "requiring phototherapy as determined by the attending neonatologist" applying the AAP guideline [7] [sponsor-reported] — a single protocol's inclusion criterion, not a description of general US practice, but the only source located this pass that names a specific clinical title as decider.

Operator — a two-tier model in one company's own description, not established more broadly

The one source that describes who physically operates the device beyond "the caregiver" is HBHM Inc., a Rhode Island home-health/DME company billing under HCPCS S9098: the service "includes delivery by a RN who will provide instruction in use and care of the bed, a daily nursing assessment with weight, a blood draw with transportation of blood to the lab, follow up with pediatrician to determine course of care, and all supplies" [4] [single-source · manufacturer]. Read plainly, this describes RN-led setup and daily monitoring with the parent operating the device between visits, not a parent operating unsupervised. This resembles, without corroborating, what a non-US qualitative study found: parents in an 8-family Swedish cohort said they felt "secure" providing home phototherapy themselves and "emphasised the importance of clear information and round-the-clock access to hospital staff" [8] [single-source] — a different country's care system, not evidence of the same structure in the US. A separate non-US implementation study's healthcare-professional focus groups named "the motivation of parents to perform home phototherapy" and clinicians' own "self-efficacy" among the facilitators of adoption [6] [single-source].

Purchaser — a DME-provider channel, confirmed by payer policy and shown concretely by two companies

No source in the domain dossier had established who purchases home phototherapy equipment in the US. CG-DME-12 answers this directly as a coverage condition: home phototherapy is medically necessary only if "Phototherapy equipment used in the home, such as a fiberoptic blanket or band, is provided by a durable medical equipment (DME) provider" [1] [single-source]. Two independent DME companies' own documents show two different versions of that channel. HBHM Inc., in-network with Blue Cross & Blue Shield of Rhode Island, states: "We will bill your insurance plan directly for this service. If your insurance plan does not cover this service, we will charge your credit card on file for the full amount due" [4] [manufacturer]. Bili Blanket Baby, operating in seven other states, instead has the family front the cost: renting requires "a valid major credit card or debit card with available credit," with a "$395.00" authorization hold at the time of rental, after which the company "will supply you with a superbill that has ICD-10 diagnosis coding (P59.9), CPT 'procedure' code (E0202), Modifier (RR- rental), Place of Service Code (H-home), our National Provider ID... and our Tax-ID/EIN that will allow you to submit a claim to your health insurance provider" [5] [manufacturer]. Between the two: the family is the immediate purchaser of record whenever the DME company is out-of-network, fronting payment and seeking reimbursement afterward; the insurer becomes the effective direct purchaser only where the company is in-network.

Payer — two independent policies, same two codes, a default steer toward home once criteria are met

CG-DME-12 [1] and Louisiana Healthcare Connections' policy [2] independently list the same two HCPCS codes for this service — E0202, "Phototherapy (bilirubin) light with photometer," and S9098, "Home visit, phototherapy services (e.g., Bili-lite), including equipment rental, nursing services, blood draw, supplies, and other services, per diem" — which, agreeing across two non-affiliated corporate payers, is stated here without a marker. Coverage is not simply permissive: CG-DME-12 states that using "more than one phototherapy device (intensive phototherapy)... in the home setting" is "not medically necessary" [1] [single-source], and the Louisiana policy states that "when criteria for home phototherapy is met, inpatient phototherapy for hyperbilirubinemia is not medically necessary unless documentation of extenuating circumstances is provided" [2] [single-source] — each payer's default position actively steers site of care toward home once its own threshold is met, not merely reimbursing whichever setting a clinician chooses. On the family's side, HBHM Inc.'s FAQ notes that even a covered per diem "could hit your deductible or that your plan requires a co-pay," and "You are responsible for paying HBHM Inc. all deductible and co-payments related to this service" [4] [single-source · manufacturer]. The Louisiana policy itself carries a "Last Review Date" of 08/2020 and cites the 2004, not the 2022, AAP guideline [2] [single-source]; whether its clinical thresholds still match the guideline's 2022 revision was not established this pass.

Patient / newborn family — one company statement of choice, no US preference survey

HBHM Inc.'s FAQ is the only source located this pass that states the family's choice explicitly, rather than describing a clinical criterion: "If you would prefer that your baby be readmitted to the hospital, you have that right. Please communicate that to your pediatrician" [4] [single-source · manufacturer]. No US patient-preference, satisfaction, or discontinuation-reason study for home phototherapy was located this pass, consistent with the domain dossier's own finding. The closest data remains the non-US qualitative study already noted, in which parents described feeling secure at home with round-the-clock access to hospital staff as important to that experience [8] [single-source].

4. Sources

[1] CG-DME-12: Home Phototherapy Devices for Neonatal Hyperbilirubinemia, Clinical UM Guideline — Healthy Blue North Carolina (Publish Date 2025-10-01; Last Review Date 2025-08-07; accessed 2026-09-01). CG-DME-12; HCPCS E0202, S9098 — https://provider.healthybluenc.com/medpolicies/healthybluenc/active/gl_pw_a053626.html [payer-policy] [2] Clinical Policy: Home Phototherapy for Neonatal Hyperbilirubinemia — Louisiana Healthcare Connections (Last Review Date 08/2020, approved 2020-08-15; accessed 2026-09-01). LA.CP.MP.150; HCPCS E0202, S9098 — https://www.louisianahealthconnect.com/content/dam/centene/louisiana-health-connect/policies/clinical-policies/LA.CP.MP.150HomePhototherapyforNeonatalHyperbilirubinemia.pdf [payer-policy] [3] Hyperbilirubinemia in Newborns: Updated Guidelines From the AAP — American Family Physician / AAFP (published 2023-06, day not given in the journal record; accessed 2026-09-01). PMID 37327148 — https://www.aafp.org/pubs/afp/issues/2023/0600/practice-guidelines-hyperbilirubinemia-newborns.html [guideline] [4] Phototherapy Information for BCBS Insurance Families — HBHM Inc. (publication date not shown in the document; accessed 2026-09-01). HCPCS S9098 — https://static1.squarespace.com/static/5745a62cf850829c62cf17be/t/5ff1fe58b6dc0c1e61dec055/1609694808757/PHOTOTHERAPY+FAQS+FOR+BCBS+FAMILIES.pdf [manufacturer] [5] Bili Blanket Rental and Insurance & Billing FAQ — Bili Blanket Baby (publication dates not shown on the pages; accessed 2026-09-01). HCPCS E0202; NPI 1134505290 — https://biliblanketbaby.com/content/insurance [manufacturer] [6] Barriers and facilitators to implementation of home phototherapy for neonatal hyperbilirubinaemia: Perspectives from healthcare professionals and parents — Midwifery (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 40043639 — https://pubmed.ncbi.nlm.nih.gov/40043639/ [peer-reviewed] [7] NCT03599258 — Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns, sponsor HonorHealth Research Institute (status completed 2021-05-27; accessed 2026-09-01). NCT03599258 — https://clinicaltrials.gov/study/NCT03599258 [trial-registry] [8] Parental experiences of home phototherapy for neonatal hyperbilirubinemia — Journal of Child Health Care (published 2023, month not given in the PubMed record; accessed 2026-09-01). PMID 35341337 — https://pubmed.ncbi.nlm.nih.gov/35341337/ [peer-reviewed]

5. Sourcing & Gaps

Well established: that home phototherapy equipment must come through a DME-provider channel, and that HCPCS E0202 and S9098 are the two codes both located payers use for it, rests on two independent, non-affiliated US payer policies (an Elevance-affiliated Medicaid/commercial plan and a Centene Medicaid subsidiary) and is stated plainly in §3.

Thin: the specific "primary provider... follow-up within 24-48 hours" language rests on the Louisiana policy alone [2]; both DME/home-health companies' billing and operator practices rest on that one company's own document each [4][5]; the "attending neonatologist" decider language rests on one trial's eligibility criterion [7]; both patient-experience and operator-motivation findings rest on the same two non-US qualitative studies already known to the domain dossier [6][8]; the Louisiana policy's own currency (last reviewed 2020, citing the 2004 AAP guideline) is a stated fact about the document, not a finding about current practice.

Rescoped from class 3: "Would parents pay out of pocket for a device without insurance backing?" is unanswerable directly; its twin — what do actual DME companies' own billing and insurance-processing pages state a family must do when the company is out-of-network or coverage is denied — is answered from [4] and [5]. "Would a clinician prefer to keep a newborn inpatient rather than release to home phototherapy?" is unanswerable directly; its twin — what do payer policies' own default coverage rules say about site of care once criteria are met — is answered from [1]'s and [2]'s "not medically necessary" language for the alternative setting.

Out of scope: CPT descriptor text (AMA-licensed; only HCPCS Level II code numbers, and Bili Blanket Baby's own mislabeling of E0202 as a "CPT" code in its superbill, are reproduced here); the national CMS DMEPOS payment/coverage cache, still absent from data/; the non-US sources ([6], [8]) are used only as directional context, never as evidence of a US practice pattern.

Not searched vs. not found: Not searched this pass — a multi-state survey of DME/home-health companies' billing practices beyond the two examined; a national HCPCS claims-volume file showing what share of E0202/S9098 billing comes from DME suppliers versus hospitals; a national-carrier (non-Medicaid-managed-care) commercial payer's coverage policy for home phototherapy. Not found — any US-specific patient-preference or satisfaction survey for home phototherapy; any source naming which specific clinician role (attending neonatologist, hospitalist, or outpatient pediatrician) signs the discharge order for home phototherapy as a matter of general US practice, as distinct from one trial's own eligibility language.

[inference] That the "primary provider willing to manage home care" condition in Louisiana's payer criteria functions as a de facto assignment of ongoing prescriber responsibility to whichever clinician commits to it is this report's own reading of [2]'s language; the policy itself does not use the word "prescriber" or assign a title.

6. Claim Candidates